Abstract
The aim of this chapter is to review the most recent aspects of hormone replacement therapy (HRT), and to clarify its impact on associated health conditions amidst growing uncertainties. Special emphasis has been placed on its effect on cardiovascular conditions and breast cancer, the two most important outcomes affected by HRT, and on identifying ideal candidates for HRT as well as defining the optimum new HRT regimens.
Chapter PDF
Similar content being viewed by others
Keywords
- Breast Cancer
- Hormone Replacement Therapy
- Invasive Breast Cancer
- Breast Cancer Rate
- Hormone Replacement Therapy User
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Rossouw JE, Anderson GL, Prentice RL et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3): 321–33
Bush TL, Cowan LD, Barrett-Connor E, et al Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA. 1983; 249(7):903–6
Grady D, Rubin SM, Petitti DB, et al Hormone therapy to prevent disease and prolong life in postmenopausal women [see comments]. Ann Intern Med. 1992;117(12):1016–37
Ragaz J, Coldman AJ. Age-matched all-cause mortality impact of hormone replacement therapy: applicability to breast cancer survivors. Breast Ca Res Treat. 1999;57:30
Grodstein F, Stampfer MJ, Colditz GA, et al Postmenopausal hormone therapy and mortality [see comments]. N Engl J Med. 1997;336(25):1769–75
Prentice RL, Anderson GL. The Women’s Health Initiative: lessons learned. Annu Rev Public Health. 2007;29:131–50
Anon. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer [see comments] [published erratum appears in Lancet 1997 Nov 15;350(9089): 1484]. Lancet. 1997;350(9084):1047–59
Ragaz J. Hormone replacement therapy in patients with a prior breast cancer history: a critical review. In: Jatoi I editor. Manual of breast disease. Lippincott Williams and Wilkins; 2002
Singletary SE. Rating the risk factors for breaat cancer. Ann Surg. 2003;4:474–82
Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. A meta-analysis of alcohol consumption in relation to risk of breast cancer. JAMA. 1988;260(5):652–6
Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women [see comments]. J Natl Cancer Inst. 1994;86(18):1403–8
Rockhill B, Willett WC, Hunter DJ, Manson JE, Hankinson SE, Colditz GA. A prospective study of recreational physical activity and breast cancer risk. Arch Intern Med. 1999;159(19):2290–6
Henderson B, Pike M, Bernestein L, Ross R. Breast cancer. 1996:1022–40
Grodstein F, Manson JE. Relationship between hormone replacement therapy, socioeconomic status, and coronary heart disease. JAMA. 2003;289(1):44
Anon. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial [see comments] [published erratum appears in JAMA 1995 Dec 6;274(21): 1676]. JAMA. 1995;273(3):199–208
Ravdin PM, Cronin KA, Howlader N, et al The decrease in breast-cancer incidence in 2003 in the United States. [see comment]. N Engl J Med. 2007;356(16):1670–4
Chlebowski RT, Kuller LH, Prentice RL, et al Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009;360(6):573–87
Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 1943;28:491–511
Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63(11–12):1727–33
Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat. 1996;38(3):325–34
Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States [see comments]. Cancer Causes Control. 1996;7(4):449–57
Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer. 1999;80(9):1453–8
Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol. 1998;16(9):3115–20
Schairer C, Gail M, Byrne C, et al Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 1999;91(3):264–70
Fowble B, Hanlon A, Freedman G, et al Postmenopausal hormone replacement therapy: effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol. 1999;17(6):1680–8
Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study [see comments]. JAMA. 1999;281(22):2091–7
Chlebowski RT, Hendrix SL, Langer RD, et al Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–53
Stefanick ML, Anderson GL, Margolis KL, et al Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647–57
Bluming AZ. A decline in breast-cancer incidence. N Engl J Med. 2007;357(5):509; author reply 513
Mosca L, Jahnige K, Giacherio D, et al Beneficial effects of hormone replacement on lipoprotein(a) levels in postmenopausal women. Prev Cardiol. 1999;2:51–8
Crouse JR 3rd, Furberg CD. Treatment of dyslipidemia: room for improvement? [In Process Citation]. Arterioscler Thromb Vasc Biol. 2000;20(11):2333–5
Bush TL, Barrett-Connor E, Cowan LD, et al Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75(6):1102–9
Clarkson TB, Williams TB, Adams MR, Wagner JD, Klein KP. Experimental effects of estrogens and progestins on the coronary artery wall. 1993:169–74
Wagner JD. Rationale for hormone replacement therapy in atherosclerosis prevention. J Reprod Med. 2000:45(3 Suppl):245–58
McGowan JA, Pottern L. Commentary on the Women’s Health Initiative. Maturitas. 2000;34(2):109–12
Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med. 1997;337(9):595–601
Adams J, Carder PJ, Downey S, et al Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000;60(11):2898–905
Wagner JD, Clarkson TB, St. Clair RW, Schwenke DC, Shively CA, Adams MR. Estrogen and progesterone replacement therapy reduces low density lipoprotein accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest. 1991;88(6):1995–2002
Steinleitner A, Stanczyk FZ, Levin JH, et al Decreased in vitro production of 6-keto-prostaglandin F1 alpha by uterine arteries from postmenopausal women. Am J Obstet Gynecol. 1989;161(6 Pt 1):1677–81
Collins P, Rosano GM, Jiang C, Lindsay D, Sarrel PM, Poole-Wilson PA. Cardiovascular protection by oestrogen-a calcium antagonist effect? Lancer. 1993;341(8855):1264–5
Mijatovic V, Kenemans P, Netelenbos JC, et al Oral 17b-estradiol continuously combined with dydrogeterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women. J Clin Endocrinol Metab. 1997;82:3543–7
Mijatovic V, van der Mooren MJ, Stehouwer CD, Netelenbos JC, Kenemans P. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol Endocrinol. 1999;13(2):130–44
Mosca L, Grundy SM, Judelson D, et al Guide to preventive cardiology for women. AHA/ACC Scientific Statement Consensus panel statement. Circulation. 1999;99(18):2480–4
Shlipak MG, Simon JA, Vittinghoff E, et al Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283(14):1845–52
Tikkanen MJ, Nikkila EA, Kuusi T. High-density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogens and norgestrel. J Clin Endocrinol Metab. 1982; 54:1113–7
Gaulin-Glasser T, Farrel WJ, Pfau SE. Modulation of circulating cellular adhesion molecules in postmenopausal women with coronary artery disease. J Am Coll Cardiol. 1998;31:1555–60
McGill HC Jr. Sex steroid hormone receptors in the cardiovascular system. Postgrad Med. 1989;Spec No: 64-8; discussion 89–90. No abstract available
Losordo DW, Kearney M, Kim EA. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation. 1996;89:1501–10
Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81(5):1680–7
Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis. 1995;38(3):199–210
Gilligan DM, Quyyumi AA, Cannon RO 3rd. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89(6):2545–51
Reis SE, Holubkov R, Young JB, White BG, Cohn JN, Feldman AM. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. J Am Coll Cardiol. 2000;36(2):529–33
Bourne T, Hillard TC, Whitehead MI, Crook D, Campbell S. Oestrogens, arterial status, and postmenopausal women [letter] [see comments]. Lancet. 1990;335(8703):1470–1
Sarrel PM, Lindsay D, Rosano GM, Poole-Wilson PA. Angina and normal coronary arteries in women: gynecologic findings. Am J Obstet Gynecol. 1992;167(2):467–71
Pines A, Fisman EZ, Levo Y, et al The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow. Am J Obstet Gynecol. 1991;164(3):806–12
Rosano GM, Panina G. Oestrogens and the heart. Therapie. 1999;54(3):381–5
Stampfer MJ, Colditz GA, Willett WC, et al Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study [see comments]. N Engl J Med. 1991;325(11):756–62
Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women [see comments]. JAMA. 1991;265(14):1861–7
Nabulsi AA, Folsom AR, White A, et al Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators [see comments]. N Engl J Med. 1993;328(15):1069–75
Grodstein F, Stampfer MJ, Manson JE, et al Postmenopausal estrogen and progestin use and the risk of cardiovascular disease [see comments] [published erratum appears in N Engl J Med 1996 Oct 31;335(18): 1406]. N Engl J Med. 1996;335(7):453–61
Hu FB, Stampfer MJ, Manson JE, et al Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women [see comments]. N Engl J Med. 2000;343(8):530–7
Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med. 2000;160(15):2263–72
Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stilman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I. Obstet Gynecol. 1991;77(2):235–40
Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins [see comments]. N Engl J Med. 1991;325(17):1196–204
Rosano GM, Panina G. Cardiovascular pharmacology of hormone replacement therapy. Drugs Aging. 1999;15(3):219–34
Harder DR, Coulson PB. Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol. 1979;100(2):375–82
Rosano GM, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease [see comments]. Lancet. 1993;342(8864):133–6
Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease. A review. Ann N Y Acad Sci. 1990;592:193–203; discussion 257–62
Hulley S, Grady D, Bush T, et al Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comments]. JAMA. 1998;280(7):605–13
Grady D, Herrington D, Bittner V, et al Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):49–57
Manson JE, Allison MA, Rossouw JE, et al Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007;356(25):2591–602
Rossouw JE, Prentice RL, Manson JE, et al Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465–77
Harman SM. Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med. 2006;3(4):254–69
Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006;15(1):35–44
Hulley S. Estrogens should not be initiated for the secondary prevention of coronary artery disease: a debate. Can J Cardiol. 2000;16(Suppl E):10E–2E
Willett WC, Manson JE, Grodstein F, Stampfer MJ, Colditz GA. RE: combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women’s Health Initiative clinical trial. Am J Epidemiol. 2006;163(11):1067–8; author reply 1068–9
Prentice RL, Langer RD, Stefanick ML, et al Combined analysis of Women’s Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol. 2006;163(7):589–99
Meade TW. Haemostatic function and ischaemic heart disease. Adv Exp Med Biol. 1984;164:3–9
Petitti DB, Wingerd J, Pellegrin F, Ramcharan S, Oral contraceptives, smoking, and other factors in relation to risk of venous thromboembolic disease. Am J Epidemiol. 1978;108(6):480–5
Barrett-Connor E. Hormone replacement and cancer. Br Med Bull. 1992;48(2):345–55
Grady D, Wenger NK, Herrington D, et al Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132(9):689–96
Devor M, Barrett-Connor E, Renvall M, Feigal D Jr, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis [see comments]. Am J Med. 1992;92(3):275–82
Danby W. HT and WHI: The Baby and the Bathwater. Personal communications. 2002
Rosing J, Tangs G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol. 1999;180:375–82
Van de Water NS, French JK, Lund MB, Hyde TA, White HD, Browett PJ. Prevalence of factor V Leiden and prothrombin variant G20210A in patients age <0 years with no significant stenosi at angiography three of four weeks after myocardial infarction. J Am Coll Cardiol. 2000;36:717–22
Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases. Am J Cardiol. 2001;87:1361–6
Herrington DM, Vittinghoff E, Howard TD, et al Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol. 2002;22(6):1012–7
Redondo M, Watzke HH, Stucki B, Sulzer I, Biasiutti FD, Binder BR, et al Coagulations factors I, V, VII, and X, prothrombin gene 20210G-A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arteriosclr Thromb Vasc Biol. 1999;78:1020–5
Anderson GL, Limacher M, Assaf AR, et al Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12
Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA. 2002;288(3):366–8
Investigators WGftWsHI; Rossouw JE, Anderson GL, et al Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33
Anderson WF, Reiner AS, Matsuno RK, et al Shifting breast cancer trends in the United States. J Clin Oncol. 2007;25(25):3923–9
Cady B, Chung MA, Michaelson JS. A decline in breast cancer incidence. N Eng J Med. 2007;357(5):509–13
Zahl PH, Maehlen J. A decline in breast-cancer incidence. N Engl J Med. 2007;357(5):510–1; author reply 513
Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ. 2004;328(7445): 921–4
Ragaz J, Spinelli JJ, Hryniuk W, Budlovsky J, Franco E. Breast cancer (BrCa) mortality reduction in the western world: therapeutic versus diagnostic interventions. Implications for cancer care organization processes. Cancer Res. 2009;69(Suppl 2):383–4
Mattsson LA, Christiansen C, Colau JC, et al Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. Am J Obstet Gynecol. 2000;182(3):545–52
Odabasi AR, Yuksel H, Demircan SS, Kacar DF, Culhaci N, Ozkara EE. A prospective randomized comparative study of the effects of intranasal and transdermal 17 beta-estradiol on postmenopausal symptoms and vaginal cytology. J Postgrad Med. 2007;53(4):221–7
Studd J, Pornel B, Marton I, et al Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group. Lancet. 1999;353(9164):1574–8
Rozenbaum H, Chevallier O, Moyal M, Durand G, Perineau M, This P. Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. Climacteric. 2002;5(3):249–58
Cicinelli E, de Ziegler D, Galantino P, et al Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol. 2002;187(3):556–60
de Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod. 2000:45(Suppl 1):149–58
Li CI, Malone KE, Porter PL, et al Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 2003;289(24):3254–63
Rossouw et al JAMA. 2007
Anderson et al JAMA. 2004
Calle EE, Miracle-McMahill HL, Thun MJ, Health CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87(7):517–23
Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years [letter] [see comments]. Lancet. 2000;355(9217):1822
Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol. 2007;25(13):1683–90
Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99(17):1335–9
Genant HK, Lucas J, Weiss SE, et al Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch Intern Med. 1997;157:2609–15
Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668–76
Grodstein F, Manson JE, Colditz GA, et al A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933–41
Harman SM, Brinton EA, Cedars M, et al KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005;8(1):3–12
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ragaz, J., Budlovsky, J. (2010). Hormone Replacement Therapy: A Critical Review. In: Jatoi, I., Kaufmann, M. (eds) Management of Breast Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-69743-5_24
Download citation
DOI: https://doi.org/10.1007/978-3-540-69743-5_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-69742-8
Online ISBN: 978-3-540-69743-5
eBook Packages: MedicineMedicine (R0)